Entera Bio Ltd. (ENTX)
1.67
-0.03 (-1.76%)
At close: Apr 01, 2025, 3:59 PM
1.67
0.27%
After-hours: Apr 01, 2025, 04:25 PM EDT
-1.76% (1D)
| Bid | 1.63 |
| Market Cap | 69.7M |
| Revenue (ttm) | 5.08M |
| Net Income (ttm) | -10.18M |
| EPS (ttm) | -0.26 |
| PE Ratio (ttm) | -6.42 |
| Forward PE | -4.24 |
| Analyst | Buy |
| Ask | 1.87 |
| Volume | 79,193 |
| Avg. Volume (20D) | 118,666 |
| Open | 1.69 |
| Previous Close | 1.70 |
| Day's Range | 1.62 - 1.75 |
| 52-Week Range | 1.41 - 3.35 |
| Beta | 1.63 |
About ENTX
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials fo...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 28, 2018
Employees 18
Stock Exchange NASDAQ
Ticker Symbol ENTX
Website https://www.enterabio.com
Analyst Forecast
According to 1 analyst ratings, the average rating for ENTX stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 498.80% from the latest price.
Stock ForecastsEarnings Surprise
Entera Bio Ltd. has released their quartely earnings
on Mar 28, 2025:
2 weeks ago
+3.72%
Entera Bio shares are trading higher after enterin...
Unlock content with
Pro Subscription
